Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dabrafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF known ✓ | P15056 | 20/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 5/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | ULK1 | O75385 | 1/20 | 1.00 |
| ▸ | ERN1 | O75460 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | KRAS | P01116 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
| ▸ | FGR | P09769 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dabrafenib SCHEMBL29353365 | 1.00 | BRAF (1.00) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL806377 | 1.00 | BRAF (1.00) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL13739419 | 0.99 | BRAF (0.98) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL29352214 | 0.97 | BRAF (0.95) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL1127269 | 0.97 | BRAF (0.95) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL14733912 | 0.95 | BRAF (0.90) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL21425052 | 0.95 | BRAF (0.90) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL2193062 | 0.95 | BRAF (0.90) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL14733909 | 0.94 | BRAF (0.89) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL2191986 | 0.92 | BRAF (0.85) | BRAFNR1I2PLK4EPHB6RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119677841-A | Preparation method of dendritic cell progenitor cells and culture medium thereof | 浙江吉量科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-116036278-B | Compositions and methods for treating cancers with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2024-12-17 | — | — | CN | claimed |
| CN-118414439-A | Novel kinase fusion by liquid biopsy | 基金会医学公司 | 2024-07-30 | — | — | CN | claimed |
| CN-117625531-A | Preparation method of dendritic cell progenitor cells and culture medium thereof | 浙江吉量科技有限公司 | 2024-03-01 | — | — | CN | claimed |
| EP-4171534-A1 | THERAPEUTICS FOR THE TREATMENT OF FSHD | UCL Business Ltd (GB) | 2023-05-03 | — | — | EP | claimed |
| CN-116036278-A | Compositions and methods for treating cancers with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| EP-4110341-A2 | A TRIPLE PHARMACEUTICAL COMBINATION COMPRISING DABRAFENIB, AN ERK INHIBITOR AND A RAF INHIBITOR | Novartis AG (CH) | 2023-01-04 | — | — | EP | claimed |
| WO-2022259157-A1 | A TRIPLE PHARMACEUTICAL COMBINATION COMPRISING DABRAFENIB, TRAMETINIB AND A SHP2 INHIBITOR | NOVARTIS AG (CH) | 2022-12-15 | — | — | WO | claimed |
| CN-115297862-A | Triple pharmaceutical combination comprising dabrafenib, an ERK inhibitor and an SHP2 inhibitor | 诺华股份有限公司 | 2022-11-04 | — | — | CN | claimed |
| CN-115279374-A | Triple pharmaceutical combination comprising dabrafenib, an ERK inhibitor and a RAF inhibitor | 诺华股份有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-122094954-A | Tricyclic quinolones and 1, 8-naphthyridin-2-one BCL6 difunctional degrading agents | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | NOVARTIS AG (CH) | 2026-05-19 | — | — | US | disclosed |
| US-20260115209-A1 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| WO-2022051567-A1 | SUBSTITUTED PYRIDO[2,3-B]PYRAZINONES AND REUATED COMPOUNDS AND THEIR USE IN TREATING MEDICAU CONDITIONS | Ikena Oncology, Inc. (US) | 2022-03-10 | — | — | WO | disclosed |
| WO-2022051565-A1 | SUBSTITUTED 4-PIPERIDINYL-QUINAZOLINES, 4-PIPERIDINYL-PYRIMIDINE-2-AMINES, AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Ikena Oncology, Inc. (US) | 2022-03-10 | — | — | WO | disclosed |
| WO-2022051568-A1 | SUBSTITUTED 4-PIPERIDINYL-PYRROLO[2,3-B]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Ikena Oncology, Inc. (US) | 2022-03-10 | — | — | WO | disclosed |
| CN-113967258-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2022-01-25 | — | — | CN | disclosed |
| CN-113956325-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | BRAF 4655/4885NR1I2 2129/4885PLK4 2930/4885 |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | CD40, CD274, ICOS | BRAF 387/4885NR1I2 3262/4885PLK4 2477/4885 |
| US-20260115209-A1 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | BRAF, MAP2K1, MOK | BRAF 1/4885NR1I2 1598/4885PLK4 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.